Tyr156

Site Information
YGPRAEEyEFLtPVE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 469606

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 12 , 27 ) , mass spectrometry ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ) , mutation of modification site ( 2 , 12 , 27 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:	breast cancer ( 1 , 26 ) , gastric cancer ( 4 , 5 , 6 , 8 , 9 ) , gastric carcinoma ( 4 , 5 , 6 , 8 , 9 ) , kidney cancer ( 14 ) , liver cancer ( 10 , 11 , 15 , 16 , 25 ) , cholangiocellular carcinoma ( 10 ) , hepatocellular carcinoma ( 15 , 16 , 25 ) , hepatocellular carcinoma, surrounding tissue ( 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ) , lung cancer ( 3 , 13 ) , non-small cell lung adenocarcinoma ( 3 ) , pancreatic cancer ( 12 ) , pancreatic carcinoma ( 12 )
Relevant cell line - cell type - tissue:	3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 27 ) , breast ( 26 ) , HeLa (cervical) ( 27 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ) , hepatocyte-liver ( 15 , 16 , 25 ) , HUVEC (endothelial) ( 2 ) , Jurkat (T lymphocyte) ( 7 ) , kidney ( 14 ) , liver ( 10 , 11 ) , lung ( 13 ) , MDA-MB-231 (breast cell) ( 1 ) , MIN6 (pancreatic) ( 12 ) , MKN-45 (gastric) ( 4 , 5 , 6 , 8 , 9 ) , PC9 (pulmonary) ( 3 ) , PC9-IR (pulmonary) ( 3 )

Upstream Regulation
Regulatory protein:	RASSF1 (mouse) ( 1 ) , Src (human) ( 1 )
Putative in vivo kinases:	Src (human) ( 27 )
Kinases, in vitro:	Src (human) ( 27 )
Treatments:	glucose ( 12 )

Downstream Regulation
Effects of modification on RhoGDI alpha:	enzymatic activity, inhibited ( 2 ) , intracellular localization ( 27 ) , molecular association, regulation ( 12 , 27 )
Effects of modification on biological processes:	carcinogenesis, induced ( 1 ) , cell motility, induced ( 1 )
Inhibit interaction with:	CDC42 iso1 (human) ( 12 , 27 ) , RAC1 (human) ( 12 , 27 ) , RHOA (human) ( 27 )

References
1	Tognoli ML, et al. (2021) RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis. EMBO J 40, e107680 34532864 Curated Info
2	Xie F, et al. (2020) Differential phosphorylation regulates the shear stress-induced polar activity of Rho-specific guanine nucleotide dissociation inhibitor α. J Cell Physiol 235 32003021 Curated Info
3	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
4	Zhou J (2012) CST Curation Set: 14007; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
5	Zhou J (2012) CST Curation Set: 14008; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
6	Rikova K (2012) CST Curation Set: 13326; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
7	Zhou J (2011) CST Curation Set: 12032; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821 Curated Info
8	Moritz A (2011) CST Curation Set: 12371; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
9	Moritz A (2011) CST Curation Set: 12373; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
10	Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640 21253578 Curated Info
11	Gu T (2010) CST Curation Set: 9480; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
12	Wang Z, Thurmond DC (2010) Differential phosphorylation of RhoGDI mediates the distinct cycling of Cdc42 and Rac1 to regulate second-phase insulin secretion. J Biol Chem 285, 6186-97 20028975 Curated Info
13	Hu Y (2010) CST Curation Set: 8947; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
14	Tucker M (2009) CST Curation Set: 7686; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
15	Gu T (2009) CST Curation Set: 7735; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
16	Gu T (2009) CST Curation Set: 7733; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
17	Tucker M (2009) CST Curation Set: 7808; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
18	Gu T (2009) CST Curation Set: 7561; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
19	Gu T (2009) CST Curation Set: 7543; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
20	Gu T (2009) CST Curation Set: 7541; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
21	Gu T (2009) CST Curation Set: 7533; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
22	Gu T (2009) CST Curation Set: 7537; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
23	Gu T (2009) CST Curation Set: 7527; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
24	Gu T (2009) CST Curation Set: 7521; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
25	Gu T (2009) CST Curation Set: 7522; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
26	Gu T (2008) CST Curation Set: 4276; Year: 2008; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
27	DerMardirossian C, Rocklin G, Seo JY, Bokoch GM (2006) Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling. Mol Biol Cell 17, 4760-8 16943322 Curated Info